Professor Mike Gorley From UK Atomic Energy Authority to Join Board of Directors of ASP Isotopes Inc.

WASHINGTON, Oct. 19, 2023 (GLOBE NEWSWIRE) -- ASP Isotopes Inc. (NASDAQ:ASPI) ("ASPI", the "Company", "us", "we" or "our"), an advanced materials company dedicated to the development of technology and processes designed to produce isotopes for use in multiple industries, today announced that Professor Mike Gorley, Chief Technologist at the UK Atomic Energy Authority is to join the board of directors of the Company.

Professor Gorley is Chief Technologist at the UK Atomic Energy Authority and a visiting Professor at the University of Bristol, U.K. He is a well-known expert in fusion technology and fusion materials. In 2014, Mike was awarded a Ph.D. (DPhil) in Materials Science from Oxford University, U.K., with a thesis on ODS steels (specialized alloys for high-performance applications). Soon after joining the UK Atomic Energy Authority in 2016, Mike directed the establishment of the Materials Technology group and supporting materials testing laboratories and led the EUROfusion Engineering Data and Design Integration group. For the past three years, Mike has served as a Strategic leader and program area manager for fusion technology at the UK Atomic Energy Authority.

Paul Mann, Chairman and CEO of ASP Isotopes Inc. said, “We are pleased to welcome Professor Gorley to the Board of Directors of ASP Isotopes. Mike has a deep understanding of materials used in the nuclear industry. Following the incorporation of Quantum Leap Energy LLC and its U.K. subsidiary, we anticipate Mike’s knowledge of the nuclear fuel supply chain will assist management in navigating the complex regulatory environment.”

Prof. Gorley commented, “The nuclear fuels that the world will require in the future are very different from those that have been used historically. Currently, there is no Western producer of fuels such as HALEU or Lithium-6. Each are critical for the development of small modular reactors and fusion energy. I look forward to working with the scientists at ASP Isotopes and Quantum Leap Energy as they try to solve the current supply chain issues that are clearly evident.”

Concurrent with Professor Gorley’s appointment, Sergey Vasnetsov will step down from the Board of Directors, but will continue to act as a consultant to the Company. Following these changes to the board of directors, the Company expects to comply with NASDAQ listing requirements regarding the number and ratio of independent and non-independent directors.

About ASP Isotopes Inc.

ASP Isotopes Inc. is an advanced materials company dedicated to developing technology and processes to produce isotopes in multiple industries. The Company employs proprietary technology, the Aerodynamic Separation Process (“ASP technology”), for the production of all isotopes. The Company’s initial focus is on producing and commercializing highly enriched isotopes for the healthcare and technology industries. The Company also plans to enrich isotopes for the nuclear energy sector. The Company has isotope enrichment facilities in Pretoria, South Africa, dedicated to the enrichment of isotopes of elements with a low atomic mass (light isotopes).

There is a growing demand for isotopes such as Silicon-28, which will enable quantum computing, and Molybdenum-100, Molybdenum-98, Zinc-68, Ytterbium-176, and Nickel-64 for new, emerging healthcare applications, as well as Chlorine-37, Lithium-6, and Uranium-235 for green energy applications. The ASP Technology (Aerodynamic Separation Process) is ideal for enriching low and heavy atomic mass molecules. For more information, please visit www.aspisotopes.com.

Forward Looking Statements

This press release contains “forward-looking statements” within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995, including, without limitation, statements relating to the expected closing of the private placement, the adequacy of resources required to achieve first revenues and the acceleration of high return-on-investment, growth projects. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only on our current beliefs, expectations, and assumptions regarding the future of our business, future plans and strategies, projections, anticipated events and trends, the economy, and other future conditions. Forward-looking statements can be identified by words such as “believes,” “plans,” “anticipates,” “expects,” “estimates,” “projects,” “will,” “may,” “might,” and words of a similar nature. Examples of forward-looking statements include, among others but are not limited to, statements we make regarding expected operating results, such as future revenues and prospects from the potential commercialization of isotopes, future performance under contracts, and our strategies for product development, engaging with potential customers, market position, and financial results. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks, and changes in circumstances that are difficult to predict, many of which are outside our control. Our actual results, financial condition, and events may differ materially from those indicated in the forward-looking statements based upon a number of factors. Forward-looking statements are not a guarantee of future performance or developments. You are strongly cautioned that reliance on any forward-looking statements involves known and unknown risks and uncertainties. Therefore, you should not rely on any of these forward-looking statements. There are many important factors that could cause our actual results and financial condition to differ materially from those indicated in the forward-looking statements, including: our reliance on the efforts of third parties; our ability to complete the construction and commissioning of our enrichment plants or to commercialize isotopes using the ASP technology or the Quantum Enrichment Process; our ability to obtain regulatory approvals for the production and distribution of isotopes; the financial terms of any current and future commercial arrangements; our ability to complete certain transactions and realize anticipated benefits from acquisitions; contracts, dependence on our Intellectual Property (IP) rights, certain IP rights of third parties; and the competitive nature of our industry. Any forward-looking statement made by us in this press release is based only on information currently available to us and speaks only as of the date on which it is made. We undertake no obligation to publicly update any forward-looking statement, whether as a result of new information, future developments or otherwise. This press release includes market and industry data and forecasts that we obtained from internal research, publicly available information and industry publications and surveys. Industry publications and surveys generally state that the information contained therein has been obtained from sources believed to be reliable. Unless otherwise noted, statements as to our potential market position relative to other companies are approximated and based on third-party data and internal analysis and estimates as of the date of this press release. We have not independently verified this information, and it could prove inaccurate. Industry and market data could be wrong because of the method by which sources obtained their data and because information cannot always be verified with certainty due to the limits on the availability and reliability of raw data, the voluntary nature of the data-gathering process and other limitations and uncertainties. In addition, we do not know all of the assumptions regarding general economic conditions or growth that were used in preparing the information and forecasts from sources cited herein. No information in this press release should be interpreted as an indication of future success, revenues, results of operation, or stock price. All forward-looking statements herein are qualified by reference to the cautionary statements set forth herein and should not be relied upon.

Contacts

Jason Assad– Investor relations
Email: Jassad@aspisotopes.com
Telephone: 561-709-3043